Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy.
Kinga Hińcza-NowakArtur KowalikAgnieszka WalczykIwona PałygaDanuta Gąsior-PerczakAgnieszka PłusaJanusz KopczyńskiMagdalena ChrapekStanisław GóźdźAldona KowalskaPublished in: Genes (2021)
Medullary thyroid cancer (MTC) is a rare malignancy that arises from calcitonin-producing C-cells. Curative treatment for patients with metastatic MTC is challenging. Identifying the mechanisms by which cancer cells inhibit the activity of immune cells provides an opportunity to develop new therapies that restore anticancer activity. Little is known about the immunological phenomena underlying MTC. Here, we examined the expression profile of 395 genes associated with MTC. The study included 51 patients diagnosed with MTC at a single center. Bioinformatical analysis revealed that CD276 expression in MTC cells was at least three-fold higher than that in normal tissue. The expression of CD276 showed a weak but statistically significant positive correlation with tumor diameter, but we did not find a significant association between CD276 expression and other histopathological clinical factors, or the response to initial therapy. A search of published data identified the monoclonal antibody (inhibitor) enoblituzumab as a potential drug for patients diagnosed with MTC overexpressing CD276.
Keyphrases
- end stage renal disease
- poor prognosis
- induced apoptosis
- ejection fraction
- newly diagnosed
- monoclonal antibody
- prognostic factors
- chronic kidney disease
- peritoneal dialysis
- randomized controlled trial
- binding protein
- oxidative stress
- signaling pathway
- mesenchymal stem cells
- patient reported outcomes
- electronic health record
- risk assessment
- rectal cancer
- human health
- long non coding rna
- big data
- smoking cessation
- artificial intelligence
- patient reported
- adverse drug
- optic nerve